[(2S)-1-[[(2S)-1-[[(2S,3S)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl] N-methyl-N-[2-[methyl(morpholine-4-carbonyl)amino]ethyl]carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(2S)-1-[[(2S)-1-[[(2S,3S)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl] N-methyl-N-[2-[methyl(morpholine-4-carbonyl)amino]ethyl]carbamate
• 化学式: C₄₀H₆₃N₇O₇
• 分子量: 754.0
• InChiKey: ROLLOXGFWONEIX-ZYADHFCISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  54
• 可旋转键数：
  19
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  161
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (2S)-N-[(2S,3S)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]-2-(methylamino)-3-[1-(4-methylphenyl)sulfonylimidazol-4-yl]propanamide 生成 [(2S)-1-[[(2S)-1-[[(2S,3S)-1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl] N-methyl-N-[2-[methyl(morpholine-4-carbonyl)amino]ethyl]carbamate
  参考文献：
  名称：

  XEHMMI, KEHJDZI;KEHJ, MASAXIRO;MARUSAVA, XIROSI;IMAI, KEHJSUKEH;KAYAKIRI,+

  摘要：

  DOI：

文献信息

• New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0300189A2

  公开（公告）日：1989-01-25

  A compound of the formula : wherein R1 is lower alkyl optionally substituted with a substituent selected from the group consisting of acyl,hydroxy, lower alkoxy, aryl, lower alkylthio and a group of the formula : in which R5 is hydrogen or acyl and R6 is hydrogen or lower alkyl; aryl; or amino optionally substituted with substituent(s) selected from the group consisting of lower alkyl and acyl; and R2 is hydrogen or lower alkyl; or R1 and R2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted with substituent(s) selected from the group consisting of lower alkyl, hydroxy(lower)alkyl, lower alkoxy(lower)alkyl, acyl(lower)alkyl, oxo and acyl; R3 is hydrogen or lower alkyl; and R4 is lower alkyl; and its pharmaceutically acceptable salt, processes for the preparation thereof and pharmaceutical composition comprising the same.

  一种式如下的化合物 其中 R1 是低级烷基，可任选被选自以下组别的取代基取代：酰基、羟基、低级烷氧基、芳基、低级烷硫基和一个式......的基团： 其中 R5 为氢或酰基，且 R6 是氢或低级烷基；芳基；或被选自低级烷基和酰基的取代基任选取代的氨基；以及 R2 是氢或低级烷基；或 R1 和 R2 与所连接的氮原子一起形成杂环基团，该杂环基团可任选被选自由低级烷基、羟基（低级）烷基、低级烷氧基（低级）烷基、酰基（低级）烷基、氧代和酰基组成的取代基取代； R3 是氢或低级烷基；和 R4 是低级烷基； 及其药学上可接受的盐、制备工艺和包含这些成分的药物组合物。
• REMEDY FOR RENAL DISEASES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0573652A1

  公开（公告）日：1993-12-15

  A remedy for renal diseases containing an amino acid derivative represented by general formula (I) or its salt as the active ingredient. In the said formula, R¹ represents optionally substituted lower alkyl, etc.; R² represents hydrogen or lower alkyl, or alternatively R¹ and R² form together with the adjacent nitrogen atom an optionally substituted heterocyclic group; R³ represents hydrogen or lower alkyl; and R⁴ represents lower alkyl.

  一种治疗肾病的药物，含有通式(I)代表的氨基酸衍生物或其盐作为活性成分。在上述式中，R¹代表任选取代的低级烷基等；R²代表氢或低级烷基，或者R¹和R²与相邻的氮原子一起形成任选取代的杂环基团；R³代表氢或低级烷基；R⁴代表低级烷基。
• NOVEL INTERMEDIATE FOR SYNTHESIS AND PRODUCTION OF AMINO ACID DERIVATIVE
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0648747A1

  公开（公告）日：1995-04-19

  A novel intermediate (II) for use in synthesis which is useful for the production of an amino acid derivative (I) having a renin-inhibiting activity, and a process for producing the derivative (I) which involves the reaction step represented by the figure, wherein R¹ represents lower alkyl, etc., which may be substituted by -NR⁷-CO-NR⁸R⁹ (wherein R⁷ represents hydrogen or lower alkyl, and R⁸ and R⁹ may be combined together with the adjacent nitrogen atom to represent an optionally substituted heterocyclic group), etc.; R² represents hydrogen, lower alkyl, etc., R³ represents hydrogen or lower alkyl; R⁴ represents hydrogen or an N-protecting group; R⁵ represents hydrogen or a carboxyl-protecting group; and R¹⁰ represents lower alkyl. This process, proceeding via the intermediate (II), is industrially advantageous because the final product (I) can be obtained in a high yield from an inexpensive starting material as compared with the conventional processes and hence the production cost can be reduced remarkably.

  一种用于合成的新型中间体（II），该中间体可用于生产具有肾素抑制活性的氨基酸衍生物（I），以及一种生产该衍生物（I）的工艺，该工艺涉及如图所示的反应步骤，其中 R¹ 代表低级烷基等、R⁷-CO-NR⁸R⁹（其中 R⁷ 代表氢或低级烷基，R⁸ 和 R𠞙 可与相邻的氮原子结合在一起代表任选取代的杂环基团）等取代；R² 代表氢、低级烷基等、R³ 代表氢或低级烷基；R⁴ 代表氢或 N 保护基团；R⁵ 代表氢或羧基保护基团；R¹⁰ 代表低级烷基。与传统工艺相比，这种通过中间体（II）进行的工艺具有工业优势，因为可以从廉价的起始原料中以高产率获得最终产品（I），从而显著降低生产成本。
• XEHMMI, KEHJDZI;KEHJ, MASAXIRO;MARUSAVA, XIROSI;IMAI, KEHJSUKEH;KAYAKIRI,+
  作者：XEHMMI, KEHJDZI、KEHJ, MASAXIRO、MARUSAVA, XIROSI、IMAI, KEHJSUKEH、KAYAKIRI,+

  DOI：——

  日期：——
• USE OF RENIN INHIBITORS FOR THE TREATMENT OF GLAUCOMA
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0617622A1

  公开（公告）日：1994-10-05